Gilead Presented P-III Trial (MYR301) Results of Hepcludex (bulevirtide) for Chronic Hepatitis Delta Virus at EASL 2023
Shots:
- The P-III trial (MYR301) evaluating bulevirtide (2mg, qd or 10mg, qd) in 150 patients. The study was based on the 48wk. data
- The results showed that patients treated with bulevirtide (2 or 10mg) achieved similar combined responses (ALT normalization & virological response) at 96wk., combined virological & biochemical response rates continued to increase through 96wk. over 48wk. response rates of 55% with 2mg & 56% with 10mg. The safety profile was consistent with 48wk. results with no resistance & no serious AEs
- In a new analysis (LBP-20), patients continued on treatment through 96wk. who experienced suboptimal virological response (non-response or partial-response) at 24wk., 43% & 82% achieved virological response who had no response or a partial-response at 24wk.
Ref: Businesswire | Image: Gilead
Related News:- Gilead Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Hepcludex (bulevirtide) for Hepatitis Delta Virus
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
